Raymond W. Anderson net worth and biography

Raymond Anderson Biography and Net Worth

Director of Monopar Therapeutics

Mr. Anderson has more than 30 years of biopharmaceutical sector experience, primarily focused in financial management. He was CFO at such notable companies as BioMarin and Dow Pharmaceutical Sciences, Inc. (now a wholly owned subsidiary of Valeant Pharmaceuticals International), and was a board member and chair of the audit committee for Raptor Pharmaceutical Corp. (now a wholly owned subsidiary of Horizon Pharma plc).

What is Raymond W. Anderson's net worth?: The estimated net worth of Raymond W. Anderson is at least $2.71 million as of August 25th, 2026. Mr. Anderson owns 23,751 shares of Monopar Therapeutics stock worth more than $2,706,189 as of August 28th. This net worth estimate does not reflect any other investments that Mr. Anderson may own. Learn More about Raymond W. Anderson's net worth.
How do I contact Raymond W. Anderson?: The corporate mailing address for Mr. Anderson and other Monopar Therapeutics executives is 1000 SKOKIE BLVD SUITE 350, WILMETTE IL, 60091. Monopar Therapeutics can also be reached via phone at 847-388-0349 and via email at [email protected]. Learn More on Raymond W. Anderson's contact information.
Has Raymond W. Anderson been buying or selling shares of Monopar Therapeutics?: During the last quarter, Raymond W. Anderson has sold $351,181.34 in shares of Monopar Therapeutics stock. Most recently, Raymond Anderson sold 3,142 shares of the business's stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $111.77, for a transaction totalling $351,181.34. Following the completion of the sale, the director now directly owns 23,751 shares of the company's stock, valued at $2,654,649.27. Learn More on Raymond W. Anderson's trading history.
Who are Monopar Therapeutics' active insiders?: Monopar Therapeutics' insider roster includes Raymond Anderson (Director), Andrew Cittadine (COO), Chandler Robinson (CEO), Christopher Starr (Director), Kim Tsuchimoto (Director), and Quan Vu (CFO). Learn More on Monopar Therapeutics' active insiders.
Are insiders buying or selling shares of Monopar Therapeutics?: In the last twelve months, Monopar Therapeutics insiders bought shares 1 times. They purchased a total of 1,500 shares worth more than $104,925.00. In the last twelve months, insiders at the sold shares 3 times. They sold a total of 557,461 shares worth more than $35,806,833.13. The most recent insider tranaction occured on August, 26th when Director Kim R Tsuchimoto sold 4,090 shares worth more than $455,585.10. Insiders at Monopar Therapeutics own 9.7% of the company. Learn More about insider trades at Monopar Therapeutics.
Information on this page was last updated on 8/26/2026.

Raymond W. Anderson Insider Trading History at Monopar Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/25/2026	Sell	3,142	$111.77	$351,181.34	23,751

Raymond W. Anderson Buying and Selling Activity at Monopar Therapeutics

Monopar Therapeutics Company Overview

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Today's Range

Now: $113.94

$112.45

$117.50

50 Day Range

MA: $105.56

$67.71

$123.84

2 Week Range

Now: $113.94

$32.77

$124.82

Volume

142,825 shs

Average Volume

246,181 shs

Market Capitalization

$764.54 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.47